Pharsight

Drugs that contain Pemigatinib

1. Pemazyre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(9 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(15 years from now)

US11628162 INCYTE CORP Methods of treating cancer with an FGFR inhibitor
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Aug 26, 2029
New Indication (I) Aug 26, 2025

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

Family Patents